A5008811878- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Autoimmune and Inflammatory Disorders Research
- Spondyloarthritis Studies and Treatments
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Psoriasis: Treatment and Pathogenesis
- Biosimilars and Bioanalytical Methods
- Immunodeficiency and Autoimmune Disorders
- T-cell and B-cell Immunology
- Chronic Myeloid Leukemia Treatments
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Hepatitis C virus research
- Peripheral Neuropathies and Disorders
- Musculoskeletal synovial abnormalities and treatments
- Systemic Sclerosis and Related Diseases
- Healthcare Systems and Practices
- Health Systems, Economic Evaluations, Quality of Life
- Musculoskeletal Disorders and Rehabilitation
- Inflammatory mediators and NSAID effects
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cytokine Signaling Pathways and Interactions
- Salivary Gland Disorders and Functions
- Tuberculosis Research and Epidemiology
Université de Montpellier
2016-2025
Centre Hospitalier Universitaire de Montpellier
2015-2024
Hôpital Lapeyronie
2015-2024
University College London
2024
Universidade Nova de Lisboa
2024
Comenius University Bratislava
2024
Bipar
2022
Institut de Génétique Moléculaire de Montpellier
2012-2021
Center for Rheumatology
2015-2021
Novartis (France)
2021
The 1987 American College of Rheumatology (ACR; formerly, the Rheumatism Association) classification criteria for rheumatoid arthritis (RA) have been criticized their lack sensitivity in early disease. This work was undertaken to develop new RA.A joint working group from ACR and European League Against developed, 3 phases, a approach classifying RA. focused on identifying, among patients newly presenting with undifferentiated inflammatory synovitis, factors that best discriminated between...
In this article, the 2010 European League against Rheumatism (EULAR) recommendations for management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs bDMARDs, respectively) have been updated. The 2013 update has developed by an international task force, which based its decisions mostly on evidence from three systematic literature reviews (one each sDMARDs, including glucocorticoids, bDMARDs safety aspects DMARD therapy); treatment...
This criteria set has been approved by the American College of Rheumatology (ACR) Board Directors and European League Against Rheumatism (EULAR) Executive Committee as Provisional.This signifies that quantitatively validated using patient data, but it not undergone validation based on an external data set.All ACR/EULAR-approved sets are expected to undergo intermittent updates.The is independent, professional, medical scientific society which does guarantee, warrant, or endorse any...
<b>Objective:</b> To formulate EULAR recommendations for the management of early arthritis. <b>Methods:</b> In accordance with EULAR's "standardised operating procedures", task force pursued an evidence based approach and on expert opinion. A steering group comprised 14 rheumatologists representing 10 European countries. The defined focus process, target population, formulated operational definition "management". Each participant was invited to propose issues interest regarding arthritis or...
Objective Remission in rheumatoid arthritis (RA) is an increasingly attainable goal, but there no widely used definition of remission that stringent achievable and could be applied uniformly as outcome measure clinical trials. This work was undertaken to develop such a definition. Methods A committee consisting members the American College Rheumatology, European League Against Rheumatism, Outcome Measures Rheumatology Initiative met guide process review prespecified analyses from RA The...
Abstract Objective To evaluate the efficacy and safety of 2 dosage regimens lyophilized certolizumab pegol (a novel PEGylated anti–tumor necrosis factor agent) as adjunctive therapy to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) an inadequate response MTX alone. Methods In this 52‐week, phase III, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial, 982 were randomized 2:2:1 receive treatment subcutaneous at initial 400 mg given weeks 0,...
<h3>Objectives</h3> Since the 2007 recommendations for management of early arthritis have been presented, considerable research has published in field arthritis, mandating an update European League Against Rheumatism (EULAR) arthritis. <h3>Methods</h3> In accordance with 2014 EULAR Standardised Operating Procedures, expert committee pursued approach that was based on evidence literature and opinion. The involved 20 rheumatologists, 2 patients 1 healthcare professional representing 12...
Abstract Introduction We analyzed the prevalence of cardiovascular (CV) disease in patients with rheumatoid arthritis (RA) and its association traditional CV risk factors, clinical features RA, use disease-modifying antirheumatic drugs (DMARDs) a multinational cross-sectional cohort nonselected consecutive outpatients RA (The Questionnaires Standard Monitoring Patients Rheumatoid Arthritis Program, or QUEST-RA) who were receiving regular care. Methods The study involved assessment by...
Abstract Objective There is no effective treatment for patients with primary Sjögren's syndrome (SS). Since tumor necrosis factor α (TNFα) could be a key element in the pathogenesis of SS, we conducted multicenter, randomized, double‐blind, placebo‐controlled trial to evaluate effect infliximab SS. Methods A total 103 SS were randomly assigned receive infusions (5 mg/kg) or placebo at weeks 0, 2, and 6 followed up 22 weeks. All fulfilled new American‐European Consensus Group criteria had...
A number of open-label studies have suggested the potential benefit rituximab (RTX) in systemic lupus erythematosus (SLE). However, 2 recent randomized controlled trials (RCTs) RTX, primary end points were not met. We undertook this study to evaluate safety and efficacy RTX off-trial patients with SLE seen regular clinical practice.We analyzed prospective data from French AutoImmunity Rituximab (AIR) registry, which includes on autoimmune disorders treated RTX.One hundred thirty-six received...
Abstract Objective To assess the safety of abatacept, a selective costimulation modulator, in patients with active rheumatoid arthritis (RA) who had been receiving ≥1 traditional nonbiologic and/or biologic disease‐modifying antirheumatic drugs (DMARDs) approved for treatment RA at least 3 months prior to entry into study. Methods This was 1‐year, multicenter, randomized, double‐blind, placebo‐controlled trial. Patients were randomized 2:1 receive abatacept fixed dose approximating 10 mg/kg...
<h3>Objectives</h3> This phase III study evaluated the efficacy and safety of rituximab plus methotrexate (MTX) in patients with active rheumatoid arthritis (RA) who had an inadequate response to MTX were naïve prior biological treatment. <h3>Methods</h3> Patients disease on stable (10–25 mg/week) randomised 2×500 mg (n=168), 2×1000 (n=172), or placebo (n=172). From week 24, not remission (Disease Activity Score (28 joints) ≥2.6) received a second course rituximab; initially assigned...
The American College of Rheumatology and the European League Against Rheumatism have developed new classification criteria for rheumatoid arthritis (RA). aim Phase 2 development process was to achieve expert consensus on clinical laboratory variables that should contribute final set.Twenty-four RA clinicians (12 from Europe 12 North America) participated in 2. A consensus-based decision analysis approach used identify factors (and their relative weights) influence probability "developing...
The risk of severe infection is a crucial factor in the assessment short-term risk:benefit ratio biologic drugs rheumatoid arthritis (RA). There no increase infections RA patients treated with rituximab (RTX) controlled trials, but this has not yet been assessed daily practice. We undertook study to investigate occurrence and factors for off-trial using data from AutoImmunity Rituximab (AIR) registry.The AIR registry was set up by French Society Rheumatology. charts were reviewed.Of enrolled...
Background During the transition to rheumatoid arthritis (RA) many patients pass through a phase characterised by presence of symptoms without clinically apparent synovitis. These are not well-characterised. This taskforce aimed define clinical characteristics with arthralgia who considered at risk for RA experts based on their experience. Methods The consisted 18 rheumatologists, 1 methodologist, 2 patients, 3 health professionals and research fellow. process had three phases. In I, list...
The provisional EULAR recommendations address several aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus, and disease caused by SARS-CoV-2, COVID-19 are meant for patients with rheumatic musculoskeletal diseases (RMD) their caregivers. A task force 20 members was convened that met times videoconferencing in April 2020. finally agreed on five overarching principles 13 covering four generic themes: (1) General measures prevention SARS-CoV-2 infection. (2)...
Objectives To evaluate clinical remission with subcutaneous abatacept plus methotrexate (MTX) and monotherapy at 12 months in patients early rheumatoid arthritis (RA), maintenance of following the rapid withdrawal all RA treatment. Methods In A ssessing V ery E arly R heumatoid T reatment phase 3b trial, active were randomised to double-blind, weekly, 125 mg MTX, monotherapy, or MTX for months. Patients low disease activity (Disease Activity Score (DAS)28 (C reactive protein (CRP)) <3.2)...